/

CMPS

COMPASS Pathways Plc - AmericanPre-market

11.53−0.47 −3.92%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delayPre-market 11.60 +0.61%

Open

12.02

Prev close

12.00

Day range

11.5312.05

52-week range

4.8815.87

Volume

1.95M0.65×

Mkt cap

1.60B

P/E ttm

—

Fwd P/E

-8.04

EPS ttm

-3.76

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−27.35%

Price Chart

Yahoo Finance · delayed

CMPSOct 12, 2026O 12.02H 12.05L 11.53C 11.53−0.47 (−3.92%)Vol 1.96M

SMA 5013.42
SMA 20010.09

1Y change +85.37% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CMPS COMPASS Pathways Plc - American · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.60%
1 month: −19.65%
3 months: −12.55%
6 months: +99.83%
Year to date: +67.10%
1 year: +85.37%

Valuation & ownership

Market cap: 1.60B
Enterprise value: 1.22B
P/E (ttm): —
Forward P/E: -8.04
PEG ratio: —
Price / book: 18.51
Price / sales (ttm): —
EV / EBITDA: -6.56
EPS (ttm): -3.76
EPS (forward): -1.43
Beta (5y monthly): 2.56
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 138.48M
Float: 106.97M
Short % of float: 12.46%
Short ratio (days): 6.08
Held by insiders: 7.62%
Held by institutions: 68.75%
Avg volume (3m): 2.99M
50-day average: 13.42
200-day average: 10.09
52-week change: +85.37%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 36.4
vs 50-day SMA: −14.05%
vs 200-day SMA: +14.31%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.03%
Realised vol (20d, ann.): 56.2%
From 52-week high: −27.35%
From 52-week low: +136.27%

ANR

Analyst Consensus

16 analysts

Consensus

Strong buy

1.31 on a 1 (strong buy) – 5 (sell) scale

Mean target

23.75

+105.98% implied

Low 13.00Median 21.00High 65.00

Recommendation trend

Now15 / 1 / 0
1m ago15 / 1 /

DES

About COMPASS Pathways Plc - American

Yahoo Finance profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Sector: Healthcare
Industry: Medical Care Facilities
Employees: 156
Headquarters: London, United Kingdom
Website: compasspathways.com
Officers: Mr. Kabir Kumar Nath M.A., M.B.A. CEO & Executive Director
Ms. Teri Loxam M.B.A. Chief Financial Officer
Dr. Guy Goodwin Chief Medical Officer
Mr. Stephen D. Schultz Senior Vice President of Investor Relations

SEAS

Seasonality · CMPS

2020–2026 · monthly returns

Strongest month Jul +26.27%Weakest month Mar −11.00%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.0	3.1	-19.9	63.8	44.2	8.3	-19.8	19.0	-7.9	-7.3			+67.1%
2025	14.0	-8.8	-27.2	39.2	4.5	-32.7	55.4	1.6	29.6	10.3	-12.2	24.3	+82.5%
2024	28.8	-8.9	-19.0	3.0	-13.9	-18.2	26.3	-2.0	-15.8	-24.4	-3.5	-17.7	−56.8%
2023	29.3	-20.5	20.4	-19.2	-8.5	12.8	12.6	-2.9	-18.2	-22.6	4.4	46.3	+9.0%
2022	-28.7	-8.3	-10.7	-29.7	0.3	19.0	44.1	4.8	-34.3	-1.8	-2.3	-22.0	−63.7%
2021	-8.0	2.9	-18.4	-1.4	-4.4	9.9	-7.0	-4.5	-11.9	41.3	-21.3	-33.4	−53.6%
2020										-8.3	55.8	-4.4	+36.5%

INSD

Insider Activity · CMPS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 25, 2026	Nath KabirChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	175K	—
Mar 25, 2026	Loxam TeriChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Mar 10, 2025	Loxam TeriChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	25K	—
Oct 23, 2024	Goldsmith George JayBeneficial Owner of more than 10% of a Class of Security	Sale at price 6.43 per share.	776.6K	$4.99M
Oct 23, 2024	Malievskaia EkaterinaBeneficial Owner of more than 10% of a Class of Security	Sale at price 6.43 per share.	1.55M	$9.99M

13F

Investors Holding CMPS

latest 13F filings of 29 followed managers

Investors holding CMPS
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$48.8M	0.32%	3.45M	+4.6%	Q2 2026
Renaissance Technologies	$20.3M	0.03%	1.43M	+65%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CMPS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CMPS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About COMPASS Pathways Plc - American

Seasonality · CMPS

Insider Activity · CMPS

Congress Trades · CMPS

Investors Holding CMPS

Investors Holding CMPS

Congress Trades · CMPS

Insider Activity · CMPS

Seasonality · CMPS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About COMPASS Pathways Plc - American

Financial Snapshot

Earnings & Dividends

News